virtual boardroom digital marketing solutions 2020€¦ · digital marketing solutions virtual...

www. proventainternational.com

&Virtual Boardroom Digital MarketingSolutions2020

PROVENTA INTERNATIONAL

CONTENTS

VIRTUAL BOARDROOM &DIGITAL MARKETING SOLUTIONS

Virtual Boardroom02.

Tailor Made Whitepapers03.

e-Shot Campaigns04.

Examples of our past virtual boardroom05-06.

VIRTUAL BOARDROOM

PROVENTA INTERNATIONAL01

VIRTUAL BOARDROOM & DIGITAL MARKETING SOLUTIONS

Virtual Boardroom

PRICE = £10,000 GBP

Access our exclusive dataset of over 50,000 director level and above executives across Europe and the US spanning from:

Position your company as a thought leader with a 30min-1 hour Virtual Boardroom with thought-provoking discussion facilitated by an expert panel.

Proventa International helps customise your Virtual Boardroom to your areas of expertise targeting specific contacts who are prequalified to ensure they are the decision maker or make up part of the decision making process.

As an extension to your business development strategy we request a target list of company names and job titles to ensure we are specifically reaching out to your key prospects as a high priority first.

Ensuring your Virtual Boardroom is highly exclusive to an end-user audience, Proventa International can create the opportunity of you being the only solution provider logged in by excluding any other vendor/competitor within your Virtual Boardroom allowing you to share your innovation in a virtual closed door environment.

Prior to each Virtual Boardroom we will provide you with the following so that you can prepare in advance understanding your audience’s buying behaviours, needs and requirements:

Following each Virtual Boardroom you will receive the email addresses of all of those who have attended to assist with your follow ups post the event.

Proventa International will host your Virtual Boardroom for the following 3-6 months as a downloadable link so that our client bank can still access it at a convenient time of their choice.

• Name• Company Name• Job Title• How many employees are they responsible for?• What is their 3 key strategic challenges?• What Drug Development Stages are they currently focusing on:• What stages of the buying cycle are they currently in: i. Request for Information ii. Request for Proposal iii. Bid Defence• How much personal budget do they have to sign off within the following 12 months?• What particular products, services or solutions are they looking for to invest in within the

following 12 months? ii. Time frame of investment iii. Main reason for investing

• Medicinal Chemistry• Biology• Bioinformatics• Oncology• Clinical Trials• Supply Chain i. Clinical ii. Commercial

• Pharmacovigilance• Manufacturing i. CMC ii. Bioprocess iii. Vaccines• Biologics• Cell and Gene Therapies

• Regulatory Affairs• Market Access & Reimbursement• Medical Devices• Human Resources• Investment & Venture Capital



Tailor Made Whitepapers

PRICE = £5,000 GBP

Engaging our audience is at the heart of what Proventa International does best hence why our tailor made Whitepapers are a perfect way to drive your content marketing strategy to those clients who really matter.

Proventa International will develop a whitepaper focusing on a specific thought leadership subject which you are well versed in co-branded with your company highlighting your specialities.

Our editorial team will research and interview industry key opinion leaders at director level and above and align key themes and topics to your current message.

Each whitepaper will be between 8-12 pages and can take between 2-3 months completed in a sleek and professional design, colour coordinated with your company’s logo and branding.

On completion of the 1st draft your team will also have the ability to have a chance to review before we go public ensuring that both parties are happy with the end goal and more importantly will attract the right target audience generating a tangible R.O.I from the downloads once published.

Proventa International will finally host a dedicated landing page which would include upon registration for each client who downloads the following which you will receive in a delegate database:

You will also receive the email addresses of all of the delegates who have downloaded the whitepaper within the following 3 months to assist with your lead generation efforts.

Proventa International will finally build and execute an integrated marketing campaign to ensure it is engaging each targeted client using a mix of direct and social media marketing.

• Name• Company Name• Job Title• e-Mail



e-Shot Campaigns

PRICE = £2,500 GBP PER E-SHOT

Proventa International can promote an existing Webinar or Thought Leadership piece being a Press Release, Article, Whitepaper or Podcast you have already created or hosting with a targeted e-shot using our prequalified dataset.

We will create a landing page for everyone to register and forward you the following:

Each e-shot will be fully GDPR compliant built from an exclusive dataset of clients where we have held strong relationships from executing our signature Strategy Meetings, Dinners and Innovation Spotlight Sessions globally since 2013.

• Name• Company Name• Job Title• e-Mail


Adis Pharmacovigilance is the expert solution for regulatory literature monitoring, from the industry-leading provider of drug safety and pharmacovigilance content. We work in partnership with you to design and deliver a tailored solution, including but not limited to services such as ICSR monitoring, local literature monitoring, on-going safety monitoring, signal monitoring, customised source coverage, special situation ICSRs, aggregated and annual reports, and Periodic Safety Update Reports. You will receive personal support every step of the way, from transition to audits, with regular reviews to keep on top of changing business needs and regulatory requirements. We look forward to meeting you.

Literature monitoring is necessary for pharmacovigilance departments, requiring significant investment in human, financial and time resources. To best meet regulatory obligations, you need an expert team and the ability to keep pace with changing guidelines. With increasing volumes of published literature and growing regulatory scrutiny, the industry is starting to outsource literature monitoring tasks to service providers.

Adis Pharmacovigilance, renowned in the field of pharmacovigilance literature monitoring, presents a unique opportunity for you to engage with other industry leaders to discuss different approaches to outsourcing and help identify the best strategy for your company.

In this exclusive roundtable you will have the opportunity to discuss:1. Is outsourcing for you? The pros and cons of outsourcing your regulatory literature monitoring 2. What are the potential efficiency gains for your PV department?3. Managing the transition from in-house to outsourced

Suzanne BerresfordGroup Product Manager, Adis Pharmacovigilance, Springer NatureSuzanne has 20 years of experience in the fields of pharmacy, medical publishing and pharmacovigilance, providing her with valuable knowledge and insights into the pharmaceutical and healthcare industries. After spending 8 years working as a clinical pharmacist and medicines information pharmacist within the UK and NZ hospital environments, Suzanne began her career in medical publishing with Adis International. Since 2006 she has worked in various roles to support the delivery of pharmacovigilance and drug safety solutions to global clients, and was promoted to Product Manager for Adis Pharmacovigilance in 2015. In her current role she is responsible for liaising with clients to identify and deliver solutions for pharmacovigilance literature monitoring, defining the product strategy, leading customer-driven product development and supporting business development.

SPEAKER

Najam ShezadSolution Specialist Databases, Adis Business Intelligence, Springer NatureNajam has been working with various pharma biotech companies helping them to choose and implement the right PV solutions for their regulatory literature screening requirements. Najam has a PhD in Organic Chemistry and worked as a medicinal chemist in UK and France.

SPEAKER

ABOUT ADIS PHARMACOVIGILANCE:

IN PARTNERSHIP WITH:

CONTACT DETAILS: Anneka Ishaq +1 (917) 831 4791 [email protected]

Outsourcing your PV literature-monitoring activities

08:00 BST / 09:00 CET / 16:00 ACT

Thursday

MAY28

ONLINE ROUNDTABLE DISCUSSION

ONLY 25 PLACES AVAILABLE

EXAMPLE OF OUR PAST VIRTUAL BOARDROOM

ABOUT ARENSIA:

CONTACT DETAILS: Anneka Ishaq +1 (917) 831 4791 [email protected]

PROVENTAI N T E R N A T I O N A L

IN PARTNERSHIP WITH:

What is the “NEW NORMAL” in early phase IMMUNO-INFLAMMATORY trials following the impact of COVID-19 pandemic?The COVID-19 pandemic has instantly impacted social life, healthcare systems and the economy. Clinical Research has been confronted with a series of unprecedented challenges which have to be solved rapidly and pragmatically in order to ensure business continuity.From the very beginning of the pandemic early March, ARENSIA EXPLORATORY MEDICINE implemented a comprehensive Business Continuity Plan (BCP) across all its research clinics in Ukraine, Romania, Moldova and Georgia. The BCP successfully ensured safety of patients and staff, keeping study supplies and logistics chains on-going.While the majority of sites across North America, Asia and Western Europe stopped or slowed down their research activities, ARENSIA´s clinics have not only achieved 100% patient retention (on-site visits) across all its clinical trials, but also continued enrolment of new patients, allowing Sponsors to progress their immunology research programs in safest manner.ARENSIA is inviting you to join a two-hour e-Workshop to address the question:What is the NEW NORMAL in early phase IMMUNO-INFLAMMATORY trials after the initial impact of COVID-19 pandemic?We will share practical insights on measures already implemented at ARENSIA’s Research Clinics and the solutions we have worked out with different Sponsors regarding patient retention and enrolment strategies in early phase immunology trials, handling monitoring activities, Site Qualification (SQV), Site Initiation visits (SIV), risk management, re-adjustments of site resources and budgets.

Moderators ARENSIA EXPLORATORY MEDICINE:Dr. Claudia Hesselmann, PhD, Co-founder & CEO, Germany Tatiana Eidus, Director Corporate Development North America, USA Dr. Angela Bischoff, PhD, Clinical Pharmacologist, Director Clinical Operations, Germany Dr. med. Eugenia Prohin, Lead Investigator, International Manager Clinical Operations, Moldova

ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary Research Clinics in Eastern Europe, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to dramatically reduce the overall number of sites, countries and recruitment periods for any early phase patient trial. Sponsors regard the recruiting speed and the data quality of ARENSIA as disruptive added value, providing them with a strategic advantage. As a testament to the excellent performance, ARENSIA is trusted by the world’s largest pharmaceutical and biotechnology companies, by global CROs, as well as by venture capital funds aiming to maximize their return of investment in small/virtual biotech companies.

The e-Workshop is limited to 25 participants only, senior leaders of global pharmaceutical and biotechnology companies worldwide focused on immune-inflammatory research. Each participant shall have the opportunity to raise questions and vividly contribute to the discussions, with the aim for all to take with them useful ideas and proven solutions how to best advance their early phase clinical trials in immunology in current times.

TIMES TO LOG IN:08:00 AM PST — PACIFIC STANDARD TIME11:00 AM EST — EASTERN STANDARD TIME04:00 PM GMT — GREENWICH MEAN TIME05:00 PM CET — CENTRAL EUROPEAN TIME06:00 PM EET — EASTERN EUROPEAN TIME

The key aspects which enable ARENSIA s clinics to ensure patient retention and continue enrolment in Phase I & II immunology trials during the COVID-19 pandemic.

Risk management / mitigation plan:• How will risk assessment change for new immunology studies?• Will new wording be added to protocols as mitigation plans? More flexibility for patient visits / procedures / home visits / tele-visits?

Re-adjustment of overall study planning:• Is now the time to consider new countries/new regions vs. over reliance on traditional site-types?• What is the new normal in regards to Sponsor-Site collaboration?• Will there be any new features/new requirements for site qualification?

Monitoring/SQV/SIV visits:• What are the critical points to consider when planning remote monitoring: how far “remote” can we go?• Update on EMA and FDA recommendations, and the standpoint of local regulatory bodies in Ukraine, Moldova, Romania, Georgia• When can we go back to on-site visits: what features of “remote” will stay as the “new standard” once the emergency situation is resolved? How new technologies can help?

AGENDA

e-WorkshopJUN17

ONLY 25 PLACES AVAILABLE RESERVE YOUR

SEAT TODAY!

EXAMPLE OF OUR PAST VIRTUAL BOARDROOM

PROVENTA INTERNATIONAL

Let’s Talk

LOUIS SMIKLE

Contact us to discusshow we can help generategrowth for your business.

Founder & CEO

[email protected]

UK HQ: +44 (0)20 3314 0100UK Mob: +44 (0)7843 894 200

virtual boardroom digital marketing solutions 2020€¦ · digital marketing solutions virtual...

Documents